By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Oncology are discussed in a new report. According to news reporting from Shanghai, People's Republic of China, by NewsRx journalists, research stated, "A major cross-cutting problem for glioma therapy is the poor extravasation and penetration of the payload drug in target glioma parenchyma. Here, to overcome these obstacles, a tumor vessel recognizing and tumor penetrating system is developed by functionalizating the poly (ethyleneglycol)-poly (L-lactic-co-glycolic acid) nanoparticles with an iNGR moiety (iNGR-NP)."
The news correspondents obtained a quote from the research from Shanghai Jiao-Tong University, "The nanoparticulate formulation is expected to achieve specific deep penetration in the tumor tissue by initially binding to aminopeptidase N, with iNGR proteolytically cleaved to CRNGR, and then bind with neuropilin-1 to mediate deep penetration in the tumor parenchyma. iNGR-NP exhibits significantly enhanced cellular uptake in human umbilical vein endothelial cells, improves the anti-proliferation and anti-tube formation abilities of paclitaxel in vitro. Following intravenous administration, iNGR-NP present favorable pharmacokinetic and tumor homing profiles. Glioma distribution and penetration assays confirm that iNGR-NP achieve the highest accumulation and deepest penetration at the glioma sites. The anti-glioma efficacy of paclitaxel-loaded iNGR-NP is verified by its improved anti-angiogenesis activity and the significantly prolonged survival time in mice bearing intracranial glioma."
According to the news reporters, the research concluded: "These evidences highlight the potential of iNGR-decorated nanoparticles in overcoming the leading edge problem in anti-glioma drug delivery."
For more information on this research see: iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas. Biomaterials, 2014;35(14):4319-4332. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting T. Kang, Shanghai Jiao Tong University, Sch Med, Inst Med Sci, Dept. of Pharmacol, Shanghai 200025, People's Republic of China. Additional authors for this research include X.L. Gao, Q.Y. Hu, D. Jiang, X.Y. Feng, X. Zhang, Q.X. Song, L. Yao, M. Huang, X.G. Jiang, Z.Q. Pang, H.Z. Chen and J. Chen (see also Oncology).
Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Drugs, Glioma, Therapy, Shanghai, Oncology, Paclitaxel, Nanoparticle, Nanotechnology, Mitotic Inhibitors, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC